18F-FDG PET in the management of endometrial cancer

Angel Chao, Ting Chang Chang, Koon Kwan Ng, Swei Hsueh, Huei Jean Huang, Hung Hsueh Chou, Chien Sheng Tsai, Tzu Chen Yen, Tzu I. Wu, Chyong Huey Lai

研究成果: 雜誌貢獻文章

76 引文 斯高帕斯(Scopus)


Purpose: Few studies have investigated the clinical impact of whole-body positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) in endometrial cancer. We aimed to assess the value of integrating FDG-PET into the management of endometrial cancer in comparison with conventional imaging alone. Methods: All patients with histologically confirmed primary advanced (stage III/IV) or suspicious/documented recurrent endometrial cancer, with poor prognostic features (serum CA-125 >35 U/ml or unfavourable cell types), or surveillance after salvage therapy were eligible. Before FDG-PET scanning, each patient had received magnetic resonance imaging and/or computed tomography (MRI-CT). The receiver operating characteristic curve method with calculation of the area under the curve (AUC) was used to compare the diagnostic efficacy. Clinical impacts were determined on a scan basis. Results: Forty-nine eligible patients were accrued and 60 studies were performed (27 primary staging, 33 post-therapy surveillance or restaging on relapse). The clinical impact was positive in 29 (48.3%) of the 60 scans. Mean standardised uptake values (SUVs) of true-positive lesions were 13.2 (range 5.7-37.4) for central pelvic lesions and 11.1 (range 1.5-37.4) for metastases. The sensitivity of FDG-PET alone (P

頁(從 - 到)36-44
期刊European Journal of Nuclear Medicine and Molecular Imaging
出版狀態已發佈 - 一月 2006

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

指紋 深入研究「18F-FDG PET in the management of endometrial cancer」主題。共同形成了獨特的指紋。

  • 引用此

    Chao, A., Chang, T. C., Ng, K. K., Hsueh, S., Huang, H. J., Chou, H. H., Tsai, C. S., Yen, T. C., Wu, T. I., & Lai, C. H. (2006). 18F-FDG PET in the management of endometrial cancer. European Journal of Nuclear Medicine and Molecular Imaging, 33(1), 36-44. https://doi.org/10.1007/s00259-005-1876-y